LONDON — The U.K.'s FTSE 100 closed higher by a whisker to keep its winning streak intact and be on par with its best run in 2017. Most other European markets closed for the May 1 holiday.

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills — the latest in a series of moves by the Danish drugmaker as it hopes to ...

Novo Nordisk A/S is partnering with U.S. biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion. The two companies will start with four ...

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

FRANKFURT, Germany — (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with ...

Meanwhile, the Ultimate 2 Bluetooth will replace the original as GameSpot's pick for the best third-party Switch controller, and we're eager to see how it stacks up with the Switch 2 Pro Controller.

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. Earlier this year, the Danish pharma traded barbs with telehealth provider Hims & Hers over the ...

Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to stem sales of copies of its popular weight-loss drug and expand access ...